Menlo Park, Calif.-based life sciences investor 5AM Ventures has filed with the Securities and Exchange Commission to raise $240 million for Fund IV. The firm, which primarily invests in early-stage life sciences, raised $220 million for Fund III, which closed in 2009, according to data from Thomson Reuters (publisher of peHUB). That fund invested in Relypsa, a Redwood City, Calif.-based developer of drugs to treat cardiovascular and renal disease and which is currently in registration for an expected $126.5 million IPO. Other portfolio company exits include Pearl Therapeutics (bought in June by AstraZeneca PLC) and Incline Therapeutics (bought by The Medicines Co. in 2012). The SEC document for 5AM’s new fund registration can be found here.